Vaishali Pharma Ltd

Vaishali Pharma Management Change

Vaishali Pharma appointed Rohil Desai and Ketur Shah as independent directors, subject to shareholder approval. The board deferred a preferential issue proposal without any decision.

Vaishali Pharma Board Meeting Date

Vaishali Pharma has scheduled an audit committee meeting for 5 November 2026. Proposed agenda includes a fund raise via preferential issue and an increase in authorised capital.

Vaishali Pharma Preferential Issue

NSE has approved the listing of 45,37,865 equity shares allotted on a preferential basis by Vaishali Pharma Ltd, effective from October 16, 2026.

Vaishali Pharma Annual General Meeting

Vaishali Pharma Limited concluded its 19th Annual General Meeting on September 24, 2026, via video conferencing, transacting routine ordinary business matters.

Vaishali Pharma Capital Structure Change

Vaishali Pharma Ltd received listing approval from NSE for 45,37,865 equity shares issued on a preferential basis, subject to depository confirmation.

Vaishali Pharma Annual General Meeting

Vaishali Pharma Limited will hold its 19th Annual General Meeting on September 24, 2026, through video conferencing to transact ordinary business.

Vaishali Pharma Management Change

Vaishali Pharma Limited announced the resignation of Mr. Bhaveshkumar Popatlal Upadhyay from the position of Non-Executive Independent Director, effective August 14, 2026.

Vaishali Pharma Q1 FY27 Results: Net Profit ₹1.5 Cr, Up 15.4% YoY

Vaishali Pharma Ltd reported revenue from operations of ₹22.9 Cr (-3.4% YoY) and net profit of ₹1.5 Cr (+15.4% YoY) for Q1 FY27.

Key figure

Net profit ₹1.5 Cr · +15.4% YoY